Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress toward valid transgenic mouse models for Alzheimer's disease.

S Y Guénette1, R E Tanzi

  • 1Department of Neurology, Massachusetts General Hospital, Charlestown 02129, USA. guenette@helix.mgh.harvard.edu

Neurobiology of Aging
|October 28, 1999
PubMed
Summary

Developing a transgenic mouse model for Alzheimer's disease (AD) requires mimicking key AD pathologies like beta-amyloid plaque accumulation and memory loss. Studies show APP and presenilin gene modifications accelerate these changes, aiding AD research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meditation and vacation effects have an impact on disease-associated molecular phenotypes.

Translational psychiatry·2016
Same author

Zinc and Alzheimer's Disease: An Update.

Nutritional neuroscience·2016
Same author

Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3.

Molecular psychiatry·2016
Same author

Rare autosomal copy number variations in early-onset familial Alzheimer's disease.

Molecular psychiatry·2013
Same author

Natural Modulators of Amyloid-Beta Precursor Protein Processing.

Current Alzheimer research·2012
Same author

Role of common and rare APP DNA sequence variants in Alzheimer disease.

Neurology·2012

Area of Science:

  • Neuroscience
  • Genetics
  • Pathology

Background:

  • Alzheimer's disease (AD) is characterized by beta-amyloid plaques, neurofibrillary tangles, and cognitive decline.
  • Transgenic mouse models are crucial for studying AD pathogenesis and testing therapies.

Purpose of the Study:

  • To outline the requirements for an ideal transgenic mouse model of Alzheimer's disease.
  • To review current progress in developing such models using amyloid precursor protein (APP) and presenilin gene modifications.

Main Methods:

  • Overexpression of mutant amyloid precursor protein (APP) alleles in mice.
  • Modification of presenilin genes to increase A beta42 peptide production.
  • Cross-breeding of genetically modified mice to combine different AD risk factors.

Related Experiment Videos

Main Results:

  • Overexpressing mutant APP leads to age-dependent beta-amyloid deposition.
  • Mutant presenilin genes increase A beta42 production but require co-expressed mutant APP for plaque formation.
  • Behavioral deficits in these models can precede detectable beta-amyloid deposition.

Conclusions:

  • Transgenic mice expressing mutant APP and presenilin genes show accelerated amyloid deposition, mimicking aspects of early-onset AD.
  • Further modifications, including "humanizing" the mouse genome, may be needed for complete AD replication.
  • These models provide valuable insights into AD pathology, including the timing of behavioral deficits relative to amyloid accumulation.